Technology ID
TAB-2907
T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies
E-Numbers
E-166-2014-0
Lead Inventor
Barrett, John (NHLBI)
Co-Inventors
Chinnasamy, Dhanalakshmi (Donna) (NHLBI)
Muranski, Pawel (NHLBI)
Buck, Christopher (NCI)
Applications
Therapeutics
Therapeutic Areas
Oncology
Infectious Disease
Immunology
Development Stages
Pre-Clinical (in vitro)
Development Status
- Early-stage
- In vitro data available
Research Products
Antibodies
Lead IC
NHLBI
ICs
NHLBI
NCI
Available for licensing are methods to generate T cells responsive to multiple polyomaviruses. The resulting T cell populations could be useful in treating immunosuppressed individuals with polyomavirus infections or polyomavirus-associated pathologies such as Merkel cell carcinoma (MCC), polyomavirus-associated nephropathy (PVAN), hemorrhagic cystitis, progressive multifocal leukoencephalopathy (PML), and trichodysplasia spinulosa (TS). The methods could also be used to restore polyomavirus-specific immunity in immunocompromised individuals.
Commercial Applications
- Immunotherapy for immunosuppressed individuals with polyomavirus-associated pathologies.
Competitive Advantages
- Methods allow development of polyomavirus antigen-specific T cells.
Licensing Contact: